New Therapy Could Protect Lung Function in COVID-19 Patients

There is an urgent need for new drugs for ARDS patients, including those with COVID-19. ARDS in influenza-infected mice is associated with reduced levels of liponucleotides (essential precursors for de novo phospholipid synthesis)... read more

New Therapy Could Protect Lung Function in COVID-19 Patients

Remestemcel-L reduces ARDS mortality in those under 65 years old

New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone. The data shows remestemcel-L reduced... read more

Remestemcel-L reduces ARDS mortality in those under 65 years old

Host Endothelial, Epithelial and Inflammatory Response in ICU COVID-19 Patients

These studies demonstrate that, unlike other well-studied causes of critical illness, endothelial dysfunction may not be characteristic of severe COVID-19 early after ICU admission. Pathways resulting in elaboration of acute... read more

Host Endothelial, Epithelial and Inflammatory Response in ICU COVID-19 Patients

Mortality Outcomes with Hydroxychloroquine and Chloroquine in COVID-19 Patients

Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate... read more

Mortality Outcomes with Hydroxychloroquine and Chloroquine in COVID-19 Patients

Virus-Induced Changes of the Respiratory Tract Environment Promote Secondary Infections

Secondary bacterial infections enhance the disease burden of influenza infections substantially. Streptococcus pneumoniae (the pneumococcus) plays a major role in the synergism between bacterial and viral pathogens, which... read more

Virus-Induced Changes of the Respiratory Tract Environment Promote Secondary Infections

On Cytokines, Fluvoxamine and COVID-19

Early in the COVID-19 pandemic, the role of ‘cytokine storm’ in patients with severe course was raised. Indeed, this triggered multiple investigations centred around calming excessive inflammation with pharmacotherapies... read more

On Cytokines, Fluvoxamine and COVID-19

Decreased Intestinal Microbiome Diversity in Pediatric Sepsis

Intestinal dysbiosis was associated with altered short-chain fatty acid metabolites in children with sepsis, but these findings were not linked directly to mitochondrial or immunologic changes. More detailed mechanistic studies... read more

Decreased Intestinal Microbiome Diversity in Pediatric Sepsis

Early Hemostatic Management of Disseminated Intravascular Coagulopathy

Inflammation and coagulation pathobiology play a significant role in the development of multiorgan failure occurring with sepsis. Inflammation induced by an infection can lead to endothelial injury, which subsequently... read more

Early Hemostatic Management of Disseminated Intravascular Coagulopathy

RECOVERY trial shows tocilizumab reduces deaths in patients hospitalised with COVID-19

The NIHR-supported RECOVERY trial has shown that tocilizumab - an anti-inflammatory rheumatoid arthritis treatment - reduces the risk of death for hospitalised patients with severe COVID-19. Researchers also found that... read more

RECOVERY trial shows tocilizumab reduces deaths in patients hospitalised with COVID-19

COVID-19: Clinical manifestations of blood cell parameters and inflammatory factors

CRP and Lymphocyte count (LYM#) showed strong correlation with disease progression, suggesting that these parameters could be used to monitor changes in patient condition. 92 patients with confirmed COVID-19 at Jingzhou... read more

COVID-19: Clinical manifestations of blood cell parameters and inflammatory factors

Inflammatory Response and Phenotyping in SARI From the MERS Coronavirus

One third of critically ill patients with Middle East respiratory syndrome (MERS) severe acute respiratory infection (SARI) and non-Middle East respiratory syndrome severe acute respiratory infection demonstrated a subphenotype... read more

Inflammatory Response and Phenotyping in SARI From the MERS Coronavirus

Adjuvant therapeutic plasma exchange in septic shock

The hallmark of sepsis is a pathological host response to an infection that may lead to organ dysfunction, shock and high mortality. Besides numerous circulating mediators initiating inflammation, vascular barrier breakdown... read more

Adjuvant therapeutic plasma exchange in septic shock

Circuits Between Infected Macrophages and T Cells in COVID-19 Pneumonia

Some patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) develop severe pneumonia and the acute respiratory distress syndrome (ARDS). Distinct clinical features in these patients have led... read more

Circuits Between Infected Macrophages and T Cells in COVID-19 Pneumonia

Critical Care Management of Infectious Meningitis and Encephalitis

Central nervous system (CNS) infections represent 2.9% of the infections encountered in the intensive care unit (ICU). Among them, infectious meningitis and encephalitis, regardless of their community or healthcare-associated... read more

Critical Care Management of Infectious Meningitis and Encephalitis

Neutrophilic Inflammation, Immunothrombosis May Distinguish Severe COVID-19 From Influenza

Severe coronavirus disease 2019 (COVID-19) is associated with immunothrombotic, neutrophil-containing vessel occlusions in the lung, with neutrophils representing the primary immune cell component associated with clinical... read more

Neutrophilic Inflammation, Immunothrombosis May Distinguish Severe COVID-19 From Influenza

Lactoferrin for the Treatment of COVID‑19

The coronavirus disease 2019 (COVID‑19) outbreak was caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). The clinical outcomes of elderly individuals and those with underlying... read more

Lactoferrin for the Treatment of COVID‑19

Endothelial Activation and Dysfunction in COVID-19

On 12 March 2020, the outbreak of coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. As of 4 August 2020, more than 18 million confirmed infections had been reported globally. Most... read more

Endothelial Activation and Dysfunction in COVID-19

Necrotizing Pancreatitis: ED Presentation, Evaluation, and Management

A 40 year-old patient presents with increasing abdominal pain and a new fever. She initially presented to the Emergency Department five days prior for upper abdominal pain. The initial workup showed stable vital signs, mildly... read more

Necrotizing Pancreatitis: ED Presentation, Evaluation, and Management

Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with COVID-19 Infection

Use of ACEI or ARBs prior to hospitalization was not associated with adverse outcomes in COVID-19 and the therapeutic benefits of continuing ACEI or ARB in hospitalized patients with COVID-19 was not offset by adverse outcomes. Data... read more

Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with COVID-19 Infection

Lipid Mediators in Critically Ill Patients: A Step Towards Precision Medicine

In this review, we provide an overview of the role of fatty acid-derived lipid mediators as endogenous regulators of the inflammatory, anti-inflammatory and pro-resolving response and future directions for use of clinical... read more

Lipid Mediators in Critically Ill Patients: A Step Towards Precision Medicine

Genetic Mechanisms of Critical Illness in COVID-19

Host-mediated lung inflammation is present, and drives mortality, in critical illness caused by COVID-19. Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development. Here... read more

Genetic Mechanisms of Critical Illness in COVID-19